A Phase 1 interventional study of NA-931 and Placebo in Overweight or Obesity and Type 2 Diabetes, sponsored by Biomed Industries, Inc.. Completed at 2 sites in Australia. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-09-27.
Sponsored by Biomed Industries, Inc. · Phase 1, Interventional, and Treatment
A randomized, double-blind, placebo-controlled, dose escalation, first in human study designed to assess the safety and tolerability, pharmacokinetics, and pharmacodynamics of NA-931 when administered as single and multiple-ascending doses in overweight/obese participants and as multiple doses in patients with T2DM.
A randomized, double-blind, placebo-controlled, dose escalation, first in human study designed to assess the safety and tolerability, pharmacokinetics, and pharmacodynamics of NA-931 when administered as single and multiple-ascending doses in overweight/obese participants and as multiple doses in patients with Type 2 Diabetes Mellitus.
NA-931 is a Quadruple Receptor Agonist for Insulin Like Growth Factor 1 (IGF-1), Glucagon-like Peptide-1 (GLP-1), Gastric Inhibitory Polypeptide (GIP) and Glucagon.
10,925 studies on the registry are indexed under Diabetes Mellitus; 1,319 are open to participants now.
This study's enrollment of 74 is close to the median of 80 across 8,367 interventional studies indexed under Diabetes Mellitus.
Browse Diabetes Mellitus studies →Biomed Industries, Inc. is the lead sponsor of 9 studies on the registry; 2 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Experimental: NA-931 Capsule of NA-931 intervention
Drug: NA-931
Placebo Comparator: Placebo Capsule of placebo
Drug: Placebo
NA-931 is a quadruple receptor agonist for weight loss
Also known as: NA-931 is a quadruple receptor agonist
Placebo of NA-931
Also known as: Placebo of NA-931
Incidence of Treatment-Emergent Adverse Events in NA-931 participants
To evaluate the safety and tolerability of NA-931
Time frame: 28 days
Maximum observe drug concentration (Cmax) of NA-931
Pharmacokinetics (PK) Cmax
Time frame: 28 days
Effect of a High-Fat Meal on Plasma Concentration of NA-931
Determine the effect of a high-fat meal on the Pharmacokinetics of NA-931following a single dose
Time frame: 28 days
Plan to share: No
No publications or documents are linked to this record.
This study is completed, as verified in Sep 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Biomed Industries, Inc.